Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8477018 | 0.87 | HPGD (0.61) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL885000 | 0.86 | MTNR1A (0.71) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL2204065 | 0.85 | NPSR1 (0.64) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL2938380 | 0.83 | KMT2A (0.69) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL13434069 | 0.83 | HPGD (0.69) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL25189340 | 0.82 | HPGD (0.68) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL1520822 | 0.81 | NPSR1 (0.68) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL14670856 | 0.80 | HPGD (0.70) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL15831228 | 0.80 | ALDH1A1 (0.75) | HPGDKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL6290075 | 0.80 | HPGD (0.70) | HPGDKMT2AMEN1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314141-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314141-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2409985-A2 | Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2314598-A1 | Inhibitors of Hepatitis C virus NS3 serine protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143312-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | HPGD 2040/4885KMT2A 3959/4885MEN1 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.